Experts present a cell-free plasma biobank and describe the role of longitudinal plasma samples for cancer research, disease monitoring, and biomarker development.
Through liquid biopsies, it is now possible to repeatedly and non-invasively interrogate the molecular landscape of solid tumors via a blood draw over the whole treatment course. Until now, liquid biopsies can be used for screening, disease monitoring and prognosis. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have been the most explored targets in this technology for commercial applications up to the present time.
In collaboration with a continuously expanding oncology network, Indivumed Services has established a unique high-quality cell-free plasma biobank that is exclusively focused on collecting longitudinal whole blood samples from cancer patients. This allows molecular insight by providing quick access to longitudinal plasma from cancer patients that have undergone treatment. ctDNA can then be isolated from longitudinal cell-free plasma to allow for monitoring of disease progression by providing diagnostic and prognostic information, potentially in real time.
Key Topics Include:
- Gain insights into Indivumed Services’ longitudinal plasma collection process
- Understand the advantages and benefits of utilizing longitudinal plasma samples for cancer research
- Explore applications of longitudinal plasma samples for biomarker research and development of companion diagnostics
To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.